Ffi Fund Ltd's Form 4 filing
Clarus Therapeutics Holdings, Inc. (CRXT) · filed Sep 21, 2021
- Accession no.
- 0001104659-21-117993
- Filed
- Sep 21, 2021, 6:38 PM ET
- Trade date
- Sep 17, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $1.17M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ffi Fund LtdCIK 0001081816 | 10% Owner |
| FYI LtdCIK 0001411786 | 10% Owner |
| Bracebridge Capital, LLCCIK 0001426486 | 10% Owner |
| Olifant Fund, Ltd.CIK 0001639809 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2021 | Common Stock | SSaleDisposed | −127,360 | $9.20F2 | −$1,171,712 | 2,102,495 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This price is a weighted-average price. These Shares were sold in multiple transactions at prices ranging from $9.05 to $9.34, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the ranges set forth in this explanatory note.
Referenced by the price of 1 transaction in Table I.